Outlook Therapeutics (OTLK) Fundamentals 2026 — Revenue Analysis | SniperIQ
Outlook Therapeutics (OTLK) is a US-listed Healthcare company in Biotechnology with a market capitalization of $54M, trading at
.31 on the NASDAQ. This SniperIQ fundamentals page covers Outlook Therapeutics's valuation, profitability (net margin -18297.5%), revenue (
M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market Cap$54M
Net Margin-18297.5%
Revenue (FY25)
M
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Outlook Therapeutics's market cap?
Outlook Therapeutics (OTLK) has a market capitalization of approximately $54M, trading at
.31 on the NASDAQ. Market cap moves with the live share price.
How profitable is Outlook Therapeutics?
Outlook Therapeutics runs a net profit margin of -18297.5%, a gross margin of -360.9%, and an operating margin of -18182.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Outlook Therapeutics generate?
Outlook Therapeutics reported revenue of
M for fiscal year 2025, with net income of -$62M and earnings per share (EPS) of -1.79. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Outlook Therapeutics pay a dividend?
Outlook Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Outlook Therapeutics financially healthy?
Outlook Therapeutics carries a debt-to-equity ratio of -0.94x and a current ratio of 0.54x, with a market beta of 0.78. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Outlook Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Outlook Therapeutics (OTLK) the key facts are: market cap $54M, revenue
M, 52-week range 0.161-3.39. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Outlook Therapeutics's full fundamentals live
Get Outlook Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.